4:34 PM · 10 October 2023

NanoString rallies over 20% after Q3 2023 earnings

NanoString Technologies (NSTG.US) is one of the best performing US stocks today. Share price is up over 20% after US biotech company reported preliminary Q3 2023 earnings. NanoString said that it expects Q3 revenue to be over $48 million, more than 60% YoY higher and above the company's own guidance range of $45-47 million (exp. $46 million). Full results will be released on Monday, November 6.

Revenue from spatial biology unit is seen at around $29 million, above the $27-28 million guidance range (exp. $27 million), while revenue from nCounter segment is seen at around $19 million, at the upper limit of the $18-19 million guidance (exp. $19 million). NanoString said that revenue in spatial biology segment increased around 348% YoY, thanks to accelerated shipments of CosMx during the quarter. Company said that strong revenue growth and improved working capital allowed it to reduce cash burn by around 50% compared to the previous quarter (from -$37 million to around -$20 million).

Taking a look at NanoString chart at H1 interval, we can see that even although today's gains are big in percentage terms, they are barely noticeable compared to recent declines the stock has suffered. Share price managed to climb above the 50-hour moving average (green line) but there is still a long way to go until the $1.75 area, where the upper limit of a local market geometry can be found.

Source: xStation5

2 November 2026, 10:33 PM

Palantir Nearly Doubles Revenue 📈 Shares Edge Higher Following Strong Earnings

2 November 2026, 10:27 PM

Apple beats Wall Street estimates 🔼 iPhone and Mac drive earnings, China disappoints

2 November 2026, 6:57 PM

Daily Summary: A Rollercoaster Ride in the Commodities Market🚨Oil Drops 7%; Gold Rallies Over 2%💥

2 November 2026, 9:21 AM

Alstom shares slump 25% in panic mode after the business guidance cut

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits